The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide The Next Fountain of Youth Craze? Peptide Injections WSJ FDA Issues Warning Letters Against Online GLP 1 Sellers BioSpace fda warning bpc 157 peptide products New Details 157 FDA moves toward easing restrictions on certain peptides BioPharma Dive